Use of Imatinib in the Prevention of Heterotopic Ossification

Abstract

Background

Heterotopic ossification (HO) is a common complication following orthopedic and trauma surgery, which may have substantial negative effects on the postoperative outcome. Angiogenesis appears to play a critical role in heterotopic ossification. One of the involved signaling molecules is platelet-derived growth factor (PDGF) which may be inhibited by imatinib.

Questions/Purposes

Our goal was to prevent HO by pharmacologically interfering with the molecular signaling pathways involved in the developmental process. We hypothesized that by administering a proven inhibitor of PDGF expression, heterotopic bone formation may be prevented.

Methods

The effect of imatinib on HO formation was studied in a murine model which reliably produces islets of HO within the soft tissue following Achilles tenotomy. The control group underwent Achilles tenotomy only. The imatinib group received imatinib mesylate. After trial completion, the limbs were harvested and scanned by micro-CT. Heterotopic bone volume was then identified and quantified.

Results

The mean volume of heterotopic bone formed in the control group was 0.976mm3 compared to 0.221 mm3 in the imatinib group. The volume of HO in the treatment group was reduced by 85% compared to the control group.

Conclusions

The administration of imatinib was associated with a significantly reduced volume of HO. This may be due to the inhibitory effect of imatinib on the PDGF signaling pathway during development of HO.

Clinical Relevance

The successful reduction of HO formation following imatinib administration has led to further insight concerning the pathogenesis of HO which in the future may lead to new clinical approaches towards the prevention of HO.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. 1.

    Alini M, Marriott A, Chen T, et al. A novel angiogenic molecule produced at the time of chondrocyte hypertrophy during endochondral bone formation. Dev Biol. 1996;176:124-132.

    PubMed  Article  CAS  Google Scholar 

  2. 2.

    Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med. 2006;354:2006-2013.

    PubMed  Article  CAS  Google Scholar 

  3. 3.

    Deckers M, Karperien M, van der Bent C, et al. Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation. Endocrinology. 2000;141:1667-1674.

    PubMed  Article  CAS  Google Scholar 

  4. 4.

    Dewar AL, Farrugia AN, Condina MR, et al. Imatinib as a potential antiresorptive therapy for bone disease. Blood. 2006;107:4334-4337.

    PubMed  Article  CAS  Google Scholar 

  5. 5.

    Fitter S, Dewar AL, Kostakis P, et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood. 2008;111:2538-2547.

    PubMed  Article  CAS  Google Scholar 

  6. 6.

    Flecknell PA. Laboratory Animal Anesthesia. London: Academic Press (Elsevier); 1996.

    Google Scholar 

  7. 7.

    Garland D. A clinical perspective on common forms of acquired heterotopic ossification. Clin Orthop Relat Res. 1991;13–29;

  8. 8.

    Goodman S, Ma T, Genovese M, et al. COX-2 selective inhibitors and bone. Int J Immunopathol Pharmacol. 2003;16:201-205.

    PubMed  CAS  Google Scholar 

  9. 9.

    Goodman S, Ma T, Trindade M, et al. COX-2 selective NSAID decreases bone ingrowth in vivo. J Orthop Res. 2002;20:1164-1169.

    PubMed  Article  CAS  Google Scholar 

  10. 10.

    Jönsson S, Olsson B, Ohlsson C, et al. Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia. Haematologica. 2008;93:1101-1103.

    PubMed  Article  Google Scholar 

  11. 11.

    McClure J. The effect of diphosphonates on heterotopic ossification in regenerating Achilles tendon of the mouse. J Pathol. 1983;139:419-430.

    PubMed  Article  CAS  Google Scholar 

  12. 12.

    Naraghi F, DeCoster T, Moneim M, et al. Heterotopic ossification. Orthopedics. 1996;19:145-151.

    PubMed  CAS  Google Scholar 

  13. 13.

    Nash TJ, Howlett CR, Martin C, et al. Effect of platelet-derived growth factor on tibial osteotomies in rabbits. Bone. 1994;15:203-208.

    PubMed  Article  CAS  Google Scholar 

  14. 14.

    O'Sullivan S, Horne A, Wattie D, et al. Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. J Clin Endocrinol Metab. 2009;94:1131-1136.

    PubMed  Article  Google Scholar 

  15. 15.

    Puzas JE, Miller MD, Rosier RN. Pathologic bone formation. Clin Orthop. 1989;245:269-281.

    PubMed  Google Scholar 

  16. 16.

    Ranly DM, McMillan J, Keller T, et al. Platelet-derived growth factor inhibits demineralized bone matrix-induced intramuscular cartilage and bone formation. A study of immunocompromised mice. J Bone Joint Surg Am. 2005;87:2052-2064.

    PubMed  Article  Google Scholar 

  17. 17.

    Roussy Y, Bertrand Duchesne MP, Gagnon G. Activation of human platelet-rich plasmas: effect on growth factors release, cell division and in vivo bone formation. Clin Oral Implants Res. 2007;18:639-648.

    PubMed  Article  Google Scholar 

  18. 18.

    Saudan M, Saudan P, Perneger T, et al. Celecoxib versus ibuprofen in the prevention of heterotopic ossification following total hip replacement: a prospective randomised trial. J Bone Joint Surg Br. 2007;89:155-159.

    PubMed  Article  CAS  Google Scholar 

  19. 19.

    van Steensel L, Paridaens D, Schrijver B, et al. Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves' ophthalmopathy. Invest Ophthalmol Vis Sci. 2009;50:3091-3098.

    PubMed  Article  Google Scholar 

  20. 20.

    Vandyke K, Dewar AL, Diamond P, et al. The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. J Bone Miner Res. 2010;25:1759-1770.

    PubMed  Article  CAS  Google Scholar 

  21. 21.

    Vandyke K, Fitter S, Dewar AL, et al. Dysregulation of bone remodeling by imatinib mesylate. Blood. 2010;115:766-774.

    PubMed  Article  CAS  Google Scholar 

  22. 22.

    Vuorinen K, Gao F, Oury TD, et al. Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia. Exp Lung Res. 2007;33:357-373.

    PubMed  Article  CAS  Google Scholar 

  23. 23.

    Yin M, Gentili C, Koyama E, et al. Antiangiogenic treatment delays chondrocyte maturation and bone formation during limb skeletogenesis. J Bone Miner Res. 2002;17:56-65.

    PubMed  Article  CAS  Google Scholar 

Download references

Acknowledgments

The study was supported by a grant of the Swiss Trauma Foundation.

Disclosures

Conflict of Interest:

Clément ML. Werner, MD, Stefan M. Zimmermann, MD, Carola C. Würgler-Hauri, MD, Joseph M. Lane, MD, Guido A. Wanner, MD, and Hans-Peter Simmen, MD have declared that they have no conflicts of interest.

Human/Animal Rights:

All institutional and national guidelines for the care and use of laboratory animals were followed.

Informed Consent

N/A

Required Author Forms

Disclosure forms provided by the authors are available with the online version of this article.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Clément M. L. Werner MD.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM1

(PDF 344 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Werner, C.M.L., Zimmermann, S.M., Würgler-Hauri, C.C. et al. Use of Imatinib in the Prevention of Heterotopic Ossification. HSS Jrnl 9, 166–170 (2013). https://doi.org/10.1007/s11420-013-9335-y

Download citation

Keywords

  • heterotopic ossification
  • prevention
  • imatinib mesylate
  • murine
  • PDGF